Investors are always looking for stocks that are poised to beat at earnings season and Veru Inc. VERU may be one such company. The firm has earnings coming up pretty soon, and events are shaping up ...

MIAMI, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate and breast cancer, ...

Earnings call Veru reported a Q1 FY2026 net loss of $5.3M, narrowing from $8.9M YoY, driven by a sharp reduction in R&D and G&A expenses. The company raised $23.4M in a public offering and now holds ...

Veru Inc. (VERU) is a great speculative biotech play to look into, despite a rejection by the FDA of the Emergency Use Authorization (EUA) of Sabizabulin for the treatment of patients with moderate to ...

SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Veru Inc. (NASDAQ: VERU) common stock between May 11, 2022 and November 9, 2022, both dates ...

Veru is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases. The Company’s drug development ...

Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...

MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

MIAMI, FL, July 22, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

Good morning, ladies and gentlemen, and welcome to Veru Inc. Investor Conference Call. All participants will be in listen-only mode. [Operator Instructions] After this morning's discussion, there will ...